Phase 2 N=31 Treatment

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

Uveitis

Bottom Line

View on ClinicalTrials.gov: NCT00525902 ↗

Enrolled (actual)

Serious AEs

3.2%

Results posted

Apr 2012

Primary outcome: Primary: Cumulative Endpoint — 21 participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Adalimumab (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Oregon Health and Science University
Primary completion: Sep 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Cumulative Endpoint	12	—
PRIMARY Cumulative Endpoint	12	—

Summary

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Eligibility Criteria

Inclusion Criteria

Patients with vision-threatening autoimmune uveitis.
Failure to respond to prednisone and at least one other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects.

Exclusion Criteria

Serious concomitant illness that could interfere with the subject's participation in the trial.
Previous or current use of cyclophosphamide.
Unable or unwilling to undergo multiple injections.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00525902). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.